Aveo's ficlatuzumab misses ORR, PFS endpoints in NSCLC trial

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) said ficlatuzumab plus gefitinib missed the primary endpoint of overall response rate vs. gefitinib alone in the Phase II portion of a Phase Ib/II trial in non-small cell lung cancer (43% vs. 40%, p-value not disclosed). Ficlatuzumab plus gefitinib also missed the secondary endpoint of median progression-free survival vs. gefitinib alone (5.6 vs. 4.7 months, p-value not disclosed). The Phase II portion enrolled 188 patients with previously untreated NSCLC. Ficlatuzumab is a human IgG1 mAb antagonist of the human hepatocyte growth factor/scatter factor (HGF/SF) ligand, a c-Met receptor activator ...